In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant (pre-operative) pembrolizumab.
‘There is a lot more anxiety here’: Scientists brace for shake-ups to health funding under Trump
In April 2017, three months after Donald Trump was inaugurated president, tens of thousands of scientists and their supporters gathered on Boston Common in the damp, chilly